Research uncovers signaling pathways related to brain-immune system linksMay 16, 2006
New research on signaling pathways in immune cells bolsters evidence of connections between the central nervous system and the immune system. The findings may also advance the scientific foundation for a potential HIV treatment that may block the virus that causes AIDS.
The cell culture study by a research team from The Children's Hospital of Philadelphia and the University of Pennsylvania appears in the Proceedings of the National Academy of Sciences, published online on May 4.
The team, led by Steven D. Douglas, M.D., chief of the Section of Immunology at The Children's Hospital of Philadelphia, analyzed neurokinin-1 receptors found on the surfaces of monocytes, immune cells that develop into macrophages. The neurokinin-1 receptors (NK-1R) are docking sites for substance P, a well-known neurotransmitter that plays important roles in both immune function and the nervous system.
In the current study, the Douglas team investigated two forms of NK-1R in a human monocyte/macrophage cell line. One was a full-length receptor, the other a shortened version with fewer amino acids. When the researchers added substance P to cell cultures with the receptors, both responded with an increase in calcium ions, but used distinct signaling pathways.
The truncated NK-IR did not respond directly to substance P, but worked through another signaling molecule, the chemokine RANTES, to increase the calcium flow. The RANTES molecule is important because it binds to another cell receptor, CCR5, which is crucial in allowing common strains of HIV (R5 strains) to infect immune cells.
Significantly, when the investigators added the drug aprepitant, which binds to NK-1R, to their cell cultures, it inhibited signaling from both the full-length and short form of the receptors.
Although the current study was not focused on HIV infection, it directly relates to broader interests of Dr. Douglas' laboratory. He currently leads a four-year program project grant from the National Institute of Mental Health, entitled, "Neurokinin-1R (Substance P Receptor) Antagonists for HIV Therapy." One project within that grant will conduct a phase 1 (safety) trial of aprepitant in adults with HIV infection. Currently used as an anti-nausea medication, aprepitant, which has the trade name Emend, might also block HIV infection.
Because macrophages are a reservoir for HIV, a strategy that denies the virus entry into those immune cells may be important in combating HIV infection. Dr. Douglas showed in 2001 that another NK-1R antagonist blocked HIV replication within macrophages in cell culture. The hope is that aprepitant may show a similar protective effect in patients.
"We postulate that blocking NK-1R may send signals to turn off the CCR5 receptor for HIV, closing the door to the virus," said Dr. Douglas. "Underlying the signaling mechanisms are the questions, 'how does the immune system talk to the nervous system?' and 'how does the nervous system talk back?' Substance P is a link between both systems, and this study increases our understanding of those underlying questions."
Children's Hospital of Philadelphia
Related Immune Cells Current Events and Immune Cells News Articles
Neuroimaging: Live from inside the cell
A novel imaging technique provides insights into the role of redox signaling and reactive oxygen species in living neurons, in real time.
Scientists find key steps linking dietary fats and colon cancer tumor growth
Scientists have shown new genetic evidence that could strengthen the link between the role of dietary fats with colon cancer progression.
New pain relief targets discovered
Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain.
Building 'Smart' Cell-Based Therapies
A Northwestern synthetic biology team has created a new technology for modifying human cells to create programmable therapeutics that could travel the body and selectively target cancer and other sites of disease.
Study sheds light on how the immune system protects children from malaria
According to a study published today in PLOS Pathogens, children who live in regions of the world where malaria is common can mount an immune response to infection with malaria parasites that may enable them to avoid repeated bouts of high fever and illness and partially control the growth of malaria parasites in their bloodstream.
Cancer drugs block dementia-linked brain inflammation, UCI study finds
A class of drugs developed to treat immune-related conditions and cancer - including one currently in clinical trials for glioblastoma and other tumors - eliminates neural inflammation associated with dementia-linked diseases and brain injuries, according to UC Irvine researchers.
Unexpected Protein Partnership Has Implications for Cancer Treatment
Scientists have identified two unlikely partners in a type of immune cell called a macrophage that work together in response to cancer drugs to increase inflammation in a way that may alter tumor growth.
New method to isolate immune cells allows researchers to study how they ward off oral diseases
Case Western Reserve University dental researchers have found a less invasive way to extract single rare immune cells from the mouth to study how the mouth's natural defenses ward off infection and inflammation.
Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease
True North Therapeutics, Inc., announced today a publication demonstrating that the company's C1s antibody prevents the destruction of human red blood cells exposed to plasma samples of patients with a type of autoimmune hemolytic anemia (AIHA).
Sensitive balance in the immune system
Apoptosis is used by cells that are changed by disease or are simply not needed any longer to eliminate themselves before they become a hazard to the body-on a cellular level, death is part of life.
More Immune Cells Current Events and Immune Cells News Articles